Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 375 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Eli Lilly and Co | LLY | NYSE | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.0% | 589.25 | 04:58:03 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 589.25 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 32 | 375 | - | 302.14 - 629.97 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 04:49:12 | 2 | $ 588.63 | USD |
Eli Lilly (LLY) Options Flow Summary
Eli Lilly and Co Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 559.38B | 949.31M | - | 28.54B | 6.24B | 6.58 | 89.57 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Eli Lilly News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical LLY Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 591.26 | 601.97 | 574.33 | 587.98 | 3,222,337 | -2.01 | -0.34% |
| 1 Month | 615.02 | 618.75 | 574.33 | 594.51 | 3,155,185 | -25.77 | -4.19% |
| 3 Months | 599.89 | 629.97 | 516.57 | 582.45 | 3,238,345 | -10.64 | -1.77% |
| 6 Months | 442.61 | 629.97 | 432.34 | 539.50 | 3,003,525 | 146.64 | 33.13% |
| 1 Year | 368.81 | 629.97 | 302.14 | 451.67 | 3,042,497 | 220.44 | 59.77% |
| 3 Years | 147.30 | 629.97 | 146.48 | 318.57 | 3,114,077 | 441.95 | 300.03% |
| 5 Years | 115.53 | 629.97 | 101.36 | 215.88 | 4,069,252 | 473.72 | 410.04% |
Eli Lilly Description
| Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. |
